Dissecting Epigenetic Silencing Complexity in the Mouse Lung Cancer Suppressor Gene Cadm1 by Reamon-Buettner, Stella Marie & Borlak, Juergen
Dissecting Epigenetic Silencing Complexity in the Mouse
Lung Cancer Suppressor Gene Cadm1
Stella Marie Reamon-Buettner*, Juergen Borlak
¤
Toxicology and Environmental Hygiene, Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany
Abstract
Disease-oriented functional analysis of epigenetic factors and their regulatory mechanisms in aberrant silencing is a
prerequisite for better diagnostics and therapy. Yet, the precise mechanisms are still unclear and complex, involving the
interplay of several effectors including nucleosome positioning, DNA methylation, histone variants and histone
modifications. We investigated the epigenetic silencing complexity in the tumor suppressor gene Cadm1 in mouse lung
cancer progenitor cell lines, exhibiting promoter hypermethylation associated with transcriptional repression, but mostly
unresponsive to demethylating drug treatments. After predicting nucleosome positions and transcription factor binding
sites along the Cadm1 promoter, we carried out single-molecule mapping with DNA methyltransferase M.SssI, which
revealed in silent promoters high nucleosome occupancy and occlusion of transcription factor binding sites. Furthermore,
M.SssI maps of promoters varied within and among the different lung cancer cell lines. Chromatin analysis with micrococcal
nuclease also indicated variations in nucleosome positioning to have implications in the binding of transcription factors
near nucleosome borders. Chromatin immunoprecipitation showed that histone variants (H2A.Z and H3.3), and opposing
histone modification marks (H3K4me3 and H3K27me3) all colocalized in the same nucleosome positions that is reminiscent
of epigenetic plasticity in embryonic stem cells. Altogether, epigenetic silencing complexity in the promoter region of
Cadm1 is not only defined by DNA hypermethylation, but high nucleosome occupancy, altered nucleosome positioning,
and ‘bivalent’ histone modifications, also likely contributed in the transcriptional repression of this gene in the lung cancer
cells. Our results will help define therapeutic intervention strategies using epigenetic drugs in lung cancer.
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Introduction
Lung cancer remains a leading cause of death, but the
molecular mechanisms of disease are largely unknown. Many
studies now show that genetic and epigenetic alterations as culprits
[1]. Epigenetic events are heritable changes in gene expression
without alterations in primary DNA sequence. They are important
in normal development and differentiation, but when misdirected
lead to diseases, notably cancer [2]. Nonetheless, many of the
processes resulting in gene silencing can be reversed with
epigenetic drugs, offering a hope for treatment and therapy [3].
The epigenetic landscape of silencing is, however, complex
involving the interplay of major effectors including nucleosome
positioning, DNA methylation, histone variants, histone modifi-
cations and non-coding RNAs [4]. How these effectors interact to
each other to affect gene expression and cause disease remains
unclear.
The DNA is packaged into a complex nucleoprotein structure in
the nucleus of a cell called chromatin, and the basic repeating unit
of chromatin is known as nucleosome, the structure and function
of which are still being elucidated [5]. Each nucleosome consists of
an octameric histone core (two copies each of H2A, H2B, H3, and
H4), around which approximately 147 bp of DNA are wrapped in
1.65 superhelical turns. Nucleosome positioning plays a crucial
role in chromatin higher order folding and in gene regulation [6–
8]. Nucleosomes can affect transcription by modulating the
accessibility of DNA to regulatory proteins and transcriptional
machinery, leading to gene activation or repression. Nucleosome
positioning can, in turn, be affected by several factors, including
DNA sequence preferences, DNA methylation, histone variants,
and histone posttranslational modifications [6]. Moreover, nucle-
osome positioning differs from nucleosome occupancy, which does
not account nucleosome starts provided that a given base pair is
inside a nucleosome [7].
Modification by DNA methylation occurs by the covalent
addition of a methyl group to position 5 of the cytosine ring,
creating 5-methylcytosine. DNA methylation is a well-known
epigenetic silencing mechanism and is associated in various
biological processes and diseases (reviews, [4,9]). Tet (ten eleven
translocation) proteins can convert 5-methylcytosine (5mC) into 5-
hydroxymethylcytosine (5hmC) [10,11], and recently also into 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC) [12]. DNA
methylation may inhibit gene expression by preventing transcrip-
tional activators from binding the DNA target or by recruitment of
methyl-CpG-binding domain (MBD) proteins, which in turn
recruit histone-modifying and chromatin-remodelling complexes
to methylated sites [4]. CpG methylation may also contribute to
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nucleosome conformation [13].
The mammalian DNA methylation machinery is mediated by
the DNA methyltransferases (DNMTs), which establish and
maintain DNA methylation patterns. DNMT1 is required in
maintaining DNA methylation patterns, while de novo methyltrans-
ferases DNMT3A and DNMT3B target new unmethylated DNA
sites (for review, [14]). Nucleosomes can influence DNA methyl-
ation, but so far studies show contrasting results. Either DNA
methyltransferases preferentially target nucleosome-bound DNA
[15], or nucleosomes render protection against methylation [16].
Furthermore, nucleosomes containing methylated DNA stabilize
de novo DNA methyltransferases 3A/3B (DNMT3A/3B) allowing
little free DNMT3A/3B to exist in the nucleus [17]. Stabilization
of DNMT3A/3B on nucleosomes in methylated regions further
promotes propagation of DNA methylation and thus ensures
faithful epigenetic inheritance. CpG methylation can also have a
distinct influence on protein binding when it is present within a
nucleosomal background [18].
Nucleosomal histones can be exchanged with histone variants,
and their incorporation can influence nucleosome positioning, and
thus gene activity (reviewed in [19]). The synthesis of canonical
histones is coupled to DNA replication in S phase, while histone
variants are synthesized throughout the cell cycle. Furthermore, in
contrast to canonical histones whose function is primarily in
genome packaging and gene regulation, non-canonical histones
have crucial roles in a range of processes, including chromosome
segregation, transcriptional regulation, and DNA repair. Among
these histone variants is the H2A variant H2A.Z, which is highly
conserved during eukaryotic evolution [20,21]. Histone variant
H2A.Z differs significantly from H2A by several amino acids and
preferentially localizes to gene promoters in mammalian cells,
where it is spread over several nucleosomes upstream and
downstream of transcription start site [22]. Another well-
conserved histone variant is H3.3, a variant that differs from
canonical H3 by few amino acid substitutions, and found to be
enriched throughout the gene body of transcribed genes, promoter
regions in active and inactive genes, and at regulatory elements.
This variant also accumulates at silent loci in pericentric
chromatin and telomeres [23].
Besides replacement of histone variants, amino acid residues in
the N-terminal tails of histones (canonical as well as variants), can
be modified by various covalent post-translational modifications
(PTMs) and form the basis for the epigenetic regulation of
chromatin structure and gene function [24]. More important,
there is crosstalk between histone modifications with other
epigenetic regulators to reinforce or reverse functions of modifi-
cations. Such PTMs, which include among others acetylation,
methylation, and phosphorylation, play a direct role in affecting
chromatin structure, or they may represent marks or signals to be
recognized by readers of histone modifications, to specify a loose
or compact chromatin [25]. Disruptions of histone modifications
in normal regulatory processes have been found in diseases,
including cancer development and progression [26].
CADM1 (cell adhesion molecule 1) is a tumor suppressor gene
identified in non-small cell lung cancer (NSCLC), but also
implicated in other human cancer diseases [27,28]. We showed
previously that Cadm1 was repressed in mouse lung cancer
progenitor cell lines, and gene expression highly correlated with
promoter hypermethylation [29]. But after treatment with the
demethylating agent 5-aza-2-deoxycytidine (5-aza-dC), most of the
cell lines were not responsive suggesting the participation of
additional epigenetic silencing events. This present study aimed to
understand epigenetic landscapes leading to transcriptional
repression of Cadm1 in the same mouse lung cancer progenitor
cells, and eventually to gain mechanistic insights into the
epigenetic silencing of tumor suppressor genes, in general, and
response to epigenetic drugs. Using bioinformatic tools, we
predicted nucleosome positions and transcription factor binding
sites along the Cadm1 promoter. We carried out a rigorous single-
molecule mapping of chromatin with the DNA methyltransferase,
M.SssI to determine nucleosome occupancy and occlusion of
transcription factor binding sites. With a panel of primers to
interrogate the middle, as well as left and right borders of
predicted nucleosomes, we analyzed for differential nucleosome
positioning in MNase-digested chromatin and ChIPed DNA with
canonical histone H2A, histone variants H2A.Z and H3.3, as well
as for histone modifications, H3K4me3 and H3K27me3.
Altogether, the lung cancer cells displayed several epigenetic
silencing events that will help to define therapeutic intervention
strategies.
Results
Cadm1 Promoter Hypermethylation Correlates with
Transcriptional Repression
This and previous study [29], found that Cadm1 promoter CpG
hypermethylation correlated with transcriptional repression in
lung cancer cell lines established from single, spontaneously
transformed lung tumor cells of c-Myc and c-Raf double-transgenic
mice. CpG methylation in individual clones was heterogeneous
within and among the 10 different lung cancer cell lines. That
previous study also demonstrated that methylation of CpGs in the
core binding sites of transcription factors Sp1, Sp3, and Zf5
abrogated DNA-protein binding. Furthermore, treatment with the
demethylating agent, 5-aza-2-deoxycytidine (5-aza-dC) restored
Cadm1 gene expression, but so far only in two cell lines, suggesting
additional epigenetic silencing events. Indeed, comparing DNA
methylation in untreated and in aza-treated lung cancer cell line
A2C12 with corresponding re-expression of Cadm1 showed that
most of the 69 CpGs analyzed in the promoter region were still
methylated in the aza-treated A2C12. Thus, treatment with 5-aza-
dC alone was not able to reinstate gene expression in all the lung
cancer cell lines or demethylate the promoter region of Cadm1 and
these observations led us to suspect for additional layers of
epigenetic silencing in place. We further investigated the Cadm1
promoter and thereby to gain insights into the extent of the
epigenetic silencing complexity in the different lung cancer cell
lines.
Nucleosome Positioning Predictions and Annotations
along the Cadm1 Promoter Region
To determine whether CpG methylation could influence
nucleosome occupancy leading to epigenetic silencing, as
previously shown [30], we used bioinformatic tools to predict
nucleosome positions, and to annotate the Cadm1 promoter
region. Using a nucleosome positioning prediction based on
genomic DNA sequence (Segal, see Materials and Methods), we
located at least five possible nucleosome positions approximately
1000 bp towards the transcription start site (TSS) and the
translation start site (ATG). The RefSeq TSS (NM_001025600.1)
is located at –21 of ATG. The predicted nucleosomes are
designated arbitrarily relative to the ATG, as nuc 1 (21011 to
2865), nuc 2 (2697 to 2551), nuc 3 (2417 to 2271), nuc 4
(2230 to 284) and nuc 5 (241 to +106). The binding sites of
predicted sequence-specific transcription factors lie at the borders
or within these nucleosomes, and highly concentrated at the
nucleosomes most adjacent to the TSS (Figure 1A). Many CpGs
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island in the promoter region of Cadm1 (Figure 1B). The 1000-
bp region is covered by five fragments of sizes 124–349 bp we
used to analyze CpG methylation in bisulfite-treated genomic
DNA, particularly in conjunction with DNA methyltransferase-
based single-molecule chromatin (MAP-IT) assay (Figure 1C,
Table S1). During the study, other nucleosome positioning
algorithms became available (e.g. NuPOP, ICM, see Materials
and Methods) and comparison showed overlap in predictions
among the three methods used (Figure 1D). Nonetheless, the
position of three nucleosomes (designated nuc 1, 3, 4) appeared
to be more or less consistent.
Single-molecule Chromatin Mapping of Cadm1 Promoter
Region with M.SssI Reveals High Nucleosome Occupancy
in Lung Cancer Cells
We next conducted a single-molecule chromatin mapping of the
Cadm1 promoter region. We utilized a footprinting strategy that
enables chromatin structure mapping at unmethylated CpG
islands by treating isolated nuclei with DNA methyltransferases,
notably the CpG-specific DNA methyltransferase (M.SssI), fol-
lowed by genomic bisulfite sequencing of individual progeny DNA
molecules [31,32]. This procedure termed as methylation-based
single promoter analysis (M-SPA), is also described as methyl-
transferase accessibility protocol for individual templates (MAP-
IT) [33]. Essentially, CpGs will be methylated by M.SssI, a
bacterial cytosine C5 methyltransferase, unless the CpGs are
blocked by nucleosomes or DNA binding proteins. To this effect,
nucleosome localization is defined as a region of about 147 bp that
is inaccessible to M.SssI.
The CpGs within the Cadm1 promoter region in normal lung
are essentially unmethylated and the gene is expressed. We treated
the chromatin of normal lung with M.SssI and analyzed protected
(unmethylated) CpGs along the promoter region of Cadm1,
especially those within predicted nucleosomes or transcription
factor binding sites. We used bisulfite primers that amplify five
fragments, three of which overlap, and cover 69 CpGs from 2944
to +41, relative to the translation start site, ATG (see Figure 1C,
Table S1). M.SssI treatment of ‘naked’ genomic DNA served as
control. Using the DNA methylation pattern in ‘naked’ genomic
DNA and normal lung as reference, we analyzed chromatin from
lung tumor, lung cancer cell lines, and a 5-aza-dC-treated lung
cancer cell line with slight gene re-expression. To gain insights of
different snapshots of the Cadm1 promoter, we compared DNA
methylation patterns of independent M.SssI treatments of same cell
lines.
Methylation efficiency of M.SssI along the Cadm1
promoter region in ‘naked’ genomic DNA
controls. Methylation efficiency of M.SssI was first determined
in ‘naked’ mouse genomic DNA. The methylation efficiency in
average 21 clones for each fragment ranged from 51–91%
(Figure S1). The highest efficiency was obtained in the two
closest fragments around the TSS, i.e. MFRA and TSFR1 at
91%. Unmethylated CpGs in these fragments were more or less
random. This differential methylation efficiency could be an
indication that the promoter region in the vicinity of TSS was
more sensitive to DNA methylation. In our previous analysis,
methylation index at fragment TSFR1 that includes the TSS
gave the clearest correlation to transcriptional repression. Overall
methylation in five fragments, 106 clones and 1,478 CpGs was
76%. Using the same protocol, we also determined the
methylation efficiency of ‘naked’ genomic DNA isolated from a
lung cancer cell line (A2Cl2) which already contained prior CpG
methylation. Overall methylation in five fragments, 31 clones
and 416 CpGs was 98%, indicating robustness of the assay.
M.SssI chromatin map of normal lung. We analyzed the
M.SssI map in chromatin isolated from nine pooled normal lungs.
For fragment BFR (255 bp, 6 CpGs 2944 to 2837), most clones
showed a stretch of unmethylated CpGs (Figure S1), especially
those which are located within a predicted nucleosome (nuc 1)
(Figure S2). For fragment 1FR (279 bp, 10 CpGs, 2682 to
2531), several clones also showed a stretch of unmethylated
CpGs, many fall within a predicted nucleosome (nuc 2) (Figure
S3). These results are suggestive of nucleosome occupancy.
For the next three overlapping fragments around the TSS
(MFR1, MFRA, TSFR1) and in the region where several
transcription factor binding sites could be found (see Figure 1A),
the patterns in most clones indicated absence of nucleosome
occupancy, but rather suggestive of binding of transcription factors
or other proteins necessary for regulation. Fragment MFR1
(124 bp, 14 CpGs, 2456 to 2341) is amplified by methylation-
specific primers (with three CpGs in both forward and reverse
primers). This fragment contains predicted binding sites for
transcription factors, for example PPARg, ER, ETF, in which
the CpGs within these binding sites were mostly unmethylated in
several clones, to suggest their binding and a possible role in the
transcriptional regulation of Cadm1. The predicted ETF site is
inside a nucleosome (nuc 3), while the PPARg is at the border of
nuc 3, and could be readily influenced by alterations concerning
the nucleosome occupancy and sliding (Figure S4).
Fragment MFRA (222 bp, 27 CpGs, 2396 to 2180) is also
amplified by methylation-specific primers (with 5 CpGs in forward
primer, 6 CpGs in reverse primer). This fragment covers a
predicted nucleosome (nuc 3), and partly that of another (nuc 4)
(Figure S5). It contains two binding sites for Sp1 which are
located within or at the left border of nuc 4. The CpGs in the Sp1
binding sites at 2224 and 2211 were occupied in many clones
having nucleosome-free pattern. This result supports further that
Sp1 may indeed play a role in the regulation of Cadm1. There were
2 of 15 clones, however, which showed a long stretch of CpG
protection inside a predicted nucleosome (nuc 3), indicating
nucleosome formation in this part of the promoter of Cadm1.
Fragment TSFR1 (345 bp, 37 CpGs, 2302 +41) is amplified by
primers that contain three CpGs on the forward primer, and two
CpGs in the reverse primer (Figure 2). Our previous results
showed that the methylation index obtained from this fragment
correlated highly with transcriptional repression as compared with
the other fragments analyzed in the Cadm1 promoter region. It
contains binding sites for Sp1, Zf5, and other predicted
transcription factors. Included also are the RefSeq transcription
start site (TSS), the translation start site, ATG as well as at least
two predicted nucleosomes (nuc 4 and nuc 5). There was no long
stretch of unmethylated CpGs, except for 3 of 15 clones in which
most of the protected CpGs fall within a predicted nucleosome
(nuc 4). In those clones without apparent occupancy of nuc 4, a
predicted nucleosome (nuc 5) where the RefSeq TSS as well as the
ATG sites are located, appeared to be not present as well,
consistent of an open chromatin that is associated with transcrip-
tion. Furthermore, the 2224 CpG in the binding site of Sp1 and
the 2192 CpG in Zf5, were frequently unmethylated, to support
their binding in the promoter region of Cadm1.
To summarize, the M.SssI methylation map observed in clones
of normal lung suggested the formation of the predicted five
nucleosomes along the promoter region of Cadm1. The patterns
found in the three fragments (MFR1, MFRA, and TSFR1) around
the TSS, in which three nucleosomes (nuc 3, nuc 4, and nuc 5) are
located, showed the absence of nucleosome occupancy in many
Epigenetic Silencing in Lung Cancer Cells
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38531Figure 1. Genomic DNA sequence-based bioinformatic predictions of nucleosome positions and transcription factor binding sites
along the promoter region of Cadm1. (A) Position of five analyzed nucleosomes (blue rectangles) and binding sites of transcription factors.
Nucleosomes are arbitrarily numbered starting from the farthest (e.g. nuc 1) towards the RefSeq transcription start site (TSS) and the translation start
site ATG, which are both located at nucleosome 5 (nuc 5). Nucleotide numbering with +1 corresponds to A of the ATG. (B) Predicted nucleosomes
and location of CpGs (vertical stripes) and the CpG island along the Cadm1 promoter. (C) Five fragments covering analyzed CpGs in bisulfite-treated
genomic DNA and predicted nucleosomes. (D) Possible nucleosome positions from three different algorithms.
doi:10.1371/journal.pone.0038531.g001
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Sp1 and Zf5 showed protection, suggesting their role in the
transcriptional regulation of Cadm1. In contrast, for the two
nucleosomes farther away from the TSS (nuc1 and nuc 2), no
apparent nucleosome remodeling appeared to take place as most
clones only exhibited long stretches of unmethylated CpGs.
Figure 2. DNA methyltransferase-based single-molecule chromatin (MAP-IT) assay of Cadm1 promoter region.( A) Methylation
patterns in clones after treatment with CpG-specific DNA methyltransferase (M.SssI) and scoring of 32 CpGs (2271 to +24 CpGs, TSFR1 fragment) in
‘naked’ mouse-tail genomic DNA, and chromatin from nine pooled normal lungs, three pooled solid lung tumors, and seven different lung cancer cell
lines with little or no Cadm1 gene expression. The patterns were obtained with BISMA where blue boxes representing unmethylated CpGs
(=protected) while red boxes, methylated CpGs. In lung tumors and lung cancer cell lines, CpG methylation could be endogenous and/or from the
M.SssI treatment. (B) Annotation of analyzed Cadm1 promoter region (CpGs, putative binding sites of lung-specific transcription factors, predicted
nucleosomes), and the corresponding sequence-context DNA methylation patterns shown in (A). A stretch of protected CpGs especially within the
predicted nucleosome 4 was frequent in many of the 84 clones obtained in lung cancer cell lines.
doi:10.1371/journal.pone.0038531.g002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38531M.SssI chromatin map of lung tumor. We analyzed the
M.SssI map of chromatin isolated from three pooled solid lung
tumors of c-Raf transgenic mice. Cadm1 was still expressed in these
tumors (not shown). Owing to endogenous CpG methylation in
the lung tumors, only results from unmethylated CpGs (i.e.
protected) after M.SssI treatment were interpreted. Nonetheless,
patterns in clones suggested the formation of at least three
nucleosomes (nuc1, nuc 2, nuc 3) (Figures S1, S2, S3, S5).A t
fragment TSFR1, where nuc 4 and nuc 5 reside, there was no long
stretch of unmethylated CpGs along the fragment to indicate
nucleosome occupancy, but 18 individual CpG sites showed
protection (Figure 2). Indeed, 13 of 19 clones exhibited the same
pattern. Among the features of these common pattern include
almost no methylation in two Sp1 binding sites (2224, 2164
CpGs), as well as that of Zf5 (2192, 2190, 2188 CpGs).
Treatment of chromatin derived from the lung tumor sample did
not show the presence of nucleosomal occupancy in analyzed
clones at fragment TSFR1. However, this result was based on
pooled lung tumors that still expressed to some degree Cadm1.
Furthermore, lung tumor is composed of many cell types including
non-cancerous ones which might have contributed to the findings
shown in Figure 2. Nonetheless, at the level of individual tumor
cell lines, marked differences in the nucleosomal positioning were
observed as discussed below.
M.SssI chromatin maps of different lung cancer cell
lines. We carried out M.SssI mapping on 10 lung cancer cell
lines with varying degrees of Cadm1 promoter hypermethylation
and transcriptional repression, as well as a lung cancer cell line
treated with 5-aza-dC. Similar to lung tumor, because of
endogenous CpG methylation in the lung cancer cell lines, only
patterns from unmethylated CpGs (i.e. protected) after M.SssI
treatment were considered. We analyzed maps of individual cell
lines (Figure S6, S7) as well as collectively. As earlier mentioned,
we also analyzed patterns in ‘naked’ genomic DNA from a lung
cancer cell line (A2C12), which was endogenously methylated (see
Figure S1C). Furthermore, to confirm results and to determine
patterns of different snapshots of the Cadm1 promoter, we have
undertaken two treatment trials in some cell lines (Figure S6).
Here, we describe the collective M.SssI maps found in the lung
cancer cell lines with little or no Cadm1 gene expression.
For fragment BFR, a stretch of at least three unmethylated
CpGs were observed in many clones. These three sites at 2944,
2924, 2903 CpGs, are located inside nuc 1 and thus, suggesting
the occupancy of this nucleosome (Figure S2). For fragment
1FR, although there were clones that displayed a stretch of at least
three unmethylated CpGs to suggest nucleosome occupancy (nuc
2), most clones were highly methylated CpGs and the source of
this methylation could be both endogenous and due to M.SssI
treatment (Figure S3).
For fragment MFR1, most of the 98 clones were highly
methylated, except for the two CpGs at 2423 and 2408. These
two CpGs are within the predicted binding sequence of
transcription factors (PPARg, ER), and are at the border of nuc
3 (Figure S4). Protection of these two CpG sites could be both
from transcription binding and nucleosome sliding. EMSA results
suggested that PPARg bind in vitro to the Cadm1 promoter with
nuclear extracts from the lung cancer cell line (A2C12), but not in
normal lung (Figure S8), and could play a role in lung cancer.
For fragment MFRA, there were five clones among 86 clones
with almost no methylation to suggest nucleosome occupancy (nuc
3) (Figure S5). There were also individual CpG sites that
exhibited low methylation, especially the Sp1 binding sites at
2224 and 2211, located at the border of a nucleosome (nuc 4)
(Figure S5). Thus, the protection in the lung cancer cell lines at
2224 and 2211 could be due to both Sp1 binding and
nucleosome occupancy.
For fragment TSFR1, most of the 84 clones displayed long
stretches of unmethylated CpGs to suggest high nucleosome
occupancy (nuc 4 and nuc 5) around the TSS (Figure 2). One
patch of protection was evident in the CpG sites 2224 to 2188;
another patch was at 2174 to 290. The binding sites for Sp1 and
Zf5 are inside a patch of unmethylated CpGs indicating occlusion
due to nucleosome occupancy. To support this assumption of a
nucleosome occupancy, the same stretch of unmethylation was
found after treating the chromatin of a lung cancer cell line (GA7)
with M.CviPI (GpC methylase), and in which the methylation of
CpG sites (= endogenous CpG methylation) was scored (data not
shown).
Lung cancer cell line (A2C12) after treatment with 5-aza-
dC. The cell line A2C12 responds to 5-aza-dC treatment
resulting in Cadm1 re-expression. However, the degree of re-
expression varies from treatment to treatment. We analyzed the
M.SssI map of 5-aza-dC-treated A2C12 which exhibited slight
Cadm1 gene re-expression and compared to non-treated A2C12
and normal lung (Figure 3). For fragment BFR, some clones now
showed stretch of unmethylated CpGs, and this result suggested
nucleosome occupancy (nuc 1). For fragment 1FR, three clones
also showed stretches of unmethylated CpGs to indicate nucleo-
some occupancy (nuc 2).
In the next three fragments towards the TSS (MFR1, MFRA,
TSFR1), some clones displayed patterns similar to normal lung,
that is indicative of patterns associated with evicted nucleosomes
and active transcription. For fragment MFR1, six clones
resembled patterns of non-nucleosome occupancy and transcrip-
tion factors binding as seen in normal lung. For fragment MFRA,
there were only four patterns observed: 7/21 complete absence of
methylation; 12/21 with the same pattern and clones appeared to
be in the process of being remodelled or nucleosome being evicted;
and 2/21 in between. The two Sp1 sites were occupied in all
clones. Thus, Sp1 is binding in those clones with evicted
nucleosomes, a finding that agrees well with our previous EMSA
results [29]. For fragment TSFR1, several clones resembled
pattern found in normal lung indicating absence of nucleosome
but transcription factor binding. This result suggested chromatin
remodeling after 5-aza-dC treatment.
Overall results M.SssI mapping. To summarize, M.SssI
mapping in normal lung supports the formation of at least five
nucleosomes at the predicted positions along the promoter region
of Cadm1. There were clones to show long stretches of
unmethylated CpGs in these positions, especially in the two
nucleosomes (nuc 1, nuc 2) upstream of TSS. The three closest
nucleosomes (nuc 3, nuc 4, nuc 5) around the TSS and in the
region where several predicted transcription factor binding sites
are located, appeared to be absent in most clones. The patterns of
these clones are suggestive of transcription factors binding or other
proteins necessary for regulation. The binding sites for Sp1 and
Zf5 were frequently unmethylated (protected) supporting further
their role in the regulation of Cadm1 expression. There were also
other frequently protected sites that require further study.
Owing to endogenous CpG methylation, it was only possible to
interpret the results in lung tumor and lung cancer cell lines from
unmethylated CpGs (i.e. protected) after M.SssI treatment. In lung
tumor in which Cadm1 was still expressed, there were stretches of
unmethylated CpGs to support formation of three nucleosomes
(nuc1, nuc 2, nuc 3). The two nucleosomes (nuc 4, nuc 5) most
adjacent to the TSS appeared to be absent in analyzed clones.
Notably, most clones displayed a common pattern involving
methylation of few CpGs, and reminiscent of transcription factor
Epigenetic Silencing in Lung Cancer Cells
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expression, results also suggested nucleosome formation (nuc 1 to
nuc 5) in the predicted nucleotide positions. Stretches of
unmethylated CpGs were frequent, especially those inside the
nucleosomes. High nucleosome occupancy was observed especially
in those three nucleosomes (nuc 3, nuc 4, nuc 5) closest to the TSS
Figure 3. M.SssI maps in normal lung, and a lung cancer cell line (A2C12) with no Cadm1 gene expression, before and after treatment
with 5-aza-dC. (A) Location of the five fragments analyzed in the Cadm1 promoter region that cover 69 CpGs 2944 to +41, relative to the
translation start site, ATG. CpGs are represented by stripes. (B-D) Methylation maps of normal lung and A2C12; blue boxes represents unmethylated
CpGs (=protected) while red boxes, methylated CpGs. The fragments are presented with respect to their location i.e. from BFR to TSFR1. The CpGs in
the core sequence of Sp1 and Zf5 binding sites are indicated by arrows. (D) After 5-aza-dC treatment and slight gene re-expression, some clones
resemble patterns found in normal lung (e.g. in TFSR1, enclosed), to suggest nucleosome remodeling (eviction) in gene expression.
doi:10.1371/journal.pone.0038531.g003
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38531and where transcription factor binding sites that include Sp1 and
Zf5 are located. In contrast to normal lung, there were no clones
to show remodeling (or eviction) with respect to these three
nucleosomes; thereby, transcription factor binding is blocked.
After 5-aza-dC treatment of a lung cancer line (A2C12) that
resulted in slight re-expression of Cadm1, remodeling was observed,
and patterns found in normal lung became evident.
Lung Cancer Cell Lines Show Differential Amplification
Efficiency after MNase Digestion of Chromatin
Further to mapping with M.SssI, we conducted chromatin
analysis with micrococcal nuclease (MNase), an enzyme that
preferentially cuts within nucleosomal linker regions and therefore
useful in determining nucleosome positions [34]. MNase digestion
of native chromatin in different samples resulted mainly in
fragments of about 150–200 bp (mononucleosomes), but not in
control ‘naked’ genomic DNA. Mononucleosomes were gel-
isolated and interrogated by normal- and quantitative-PCR using
a panel of PCR primers (see Table S2) amplifying within or at the
left or right boundaries of predicted nucleosomes (Figure 4,
Figures S9, S10). The PCR products obtained with ‘middle’
(65–113 bp), ‘left’ (132–168 bp), and ‘right’ (93–222 bp) primers
were verified by sequencing. The ‘naked’ genomic DNA was
completely digested and no expected PCR products were obtained
(Figure S9).
We were able to amplify fragments for the five predicted
nucleosomes in MNase-digested chromatin in normal lung, lung
tumor and in the different lung cancer cell lines, suggesting
nucleosomal nature of DNA (Figure 4). Primers designed to
amplify products inside nucleosomes exhibited higher efficiency
(banding intensity and/or qPCR values), than those primers that
amplify bigger products and/or shifted to the left or right borders
of nucleosomes. Furthermore, amplification efficiency differed
among the lung cancer cell lines and was generally higher in cell
lines which were less methylated and still expressed Cadm1. Such
differences became more evident with the left or right border
primers that in some cell lines amplification products were already
absent. This result suggested differential nucleosome positioning
among the different lung cancer cell lines. Overall, the highest
amplification efficiency was observed in normal lung, then in lung
tumor, and followed by the lung cancer cell lines.
To determine whether sequence alterations leading to variations
in MNase digestions could be the cause for differential amplifi-
cation efficiency, we sequenced the Cadm1 promoter region in the
different lung cancer cell lines. No sequence alterations were
found. Since the use of native (non-fixed) chromatin may lead to
sliding, we also compared PCR products from independent
MNase digestions of native and formaldehyde-fixed chromatin
from a lung cancer cell line (GD12, not shown). Expected PCR
products were obtained. To test further the validity of our PCR
protocol, we used primer pairs that span different nucleosomes or
with bigger products. For instance, only few cell lines were positive
to primer pair nuc 5 (nuc5BF/5BR) at 222 bp (Figure S9). These
control experiments thus support reliability of obtained results
during MNase chromatin analysis.
ChIP Corroborates High Nucleosome Occupancy
Associated with Cadm1 Silencing in Lung Cancer Cells
We performed chromatin immunoprecipitation (ChIP) firstly, to
confirm the nucleosomal nature of analyzed DNA fragments
during M.SssI mapping and MNase chromatin analysis, and
secondly, to gain insights into the role of histone variants and
modifications, which could affect nucleosome stability and
positioning, in the transcriptional repression of Cadm1 in the lung
cancer cells. Essentially, ChIP experiments were undertaken on
native chromatin (N-ChIP), in which chromatin was isolated using
a buffer with 140 mM NaCl, and an MNase digestion giving
mainly 150–200 bp fragments. Other salt conditions during
chromatin preparation may influence nucleosome profile [35].
For the subsequent ChIP-PCR, we used the same panel of primers
described previously in amplifying fragments from MNase-
digested chromatin.
N-ChIPandX-ChIPwiththecanonicalhistoneH2A. After
N-ChIP with the canonical histone H2A, we could amplify most
expected fragments from the five predicted nucleosomes in A2C12,
a lung cancer line with no Cadm1 gene expression (Figure S11).
Similar to MNase results, the intensity of amplification products
insidenucleosomeswashigherthanthosethatincludednucleosome
borders, in agreement of sequences within the nucleosome core.
This result evidencing nucleosome formation and occupancy at the
givennucleotidepositionshasbeenconfirmedinindependentChIP
experiments. Indeed, to allay concerns of nucleosome re-arrange-
ments during N-ChIP, we conducted a parallel experiment that
included crosslinking of chromatin with formaldehyde (X-ChIP),
differentprotocolforisolatingandshearingofchromatin,andChIP
conditions(seeMethodsS1).X-ChIPwithH2A,onacellline(A2B1)
with Cadm1 gene expression, and three cell lines (GA7, GD12,
A2C12), without Cadm1 expression, yielded expected fragments
confirmingearlier results withN-ChIP(Figure S11).Consistentof
nucleosome depletion in gene expression, the quantity of amplified
fragments in A2B1 was lesser than those cell lines without gene
expression.Conversely,thisresultalsosuggestedhighernucleosome
occupancyassociatedwithtranscriptionalrepressionofCadm1inthe
lung cancer cell lines.
ComparisonofH2AandH2A.Znucleosomesinlungcancer
cell lines with different gene expressions. Replacement of
H2A with the histone variant H2A.Z could result in the sliding of
nucleosomes to different positions, and would thereby affect gene
expression [19]. To investigate such possibility, we compared ChIP
resultsobtainedwithH2AandH2A.Zondifferentnucleosomes,ina
cell linewithCadm1expression(A2B1) andacell linewithoutCadm1
expression (A2C12). N-ChIP and normal PCR using 2 mL of ChIP
DNA showed amplification of both H2A and H2A.Z on nucleo-
somes around the TSS in the promoter region of Cadm1 (Figure
S12B). Sequencing of these PCR products from the ChIP DNA
with H2A and H2A.Z confirmed results. Furthermore, banding
intensitiesshowedoverallthatH2AwasgreaterthanH2A.Zinboth
cell lines, but the quantity of H2A and H2A.Z was higher in the cell
line without Cadm1 gene expression, suggesting higher nucleosome
occupancy associated with silencing of the gene. Indeed, in some
primersetsinterrogatingnucleosomeborders,onlyH2AandH2A.Z
from A2C12 could be amplified to imply also differential
nucleosome positioning between A2B1 and A2C12. Furthermore,
for extreme primer sets, e.g. nuc 4 (4F3/4R) with an expected
product of 168 bp, only H2A from A2C12 gave a product, to
likewise suggest different positioning between H2A and H2A.Z
nucleosomes.
On the same ChIP experiment, we carried out quantitative
PCR using four primer sets to assay four nucleosomes upstream of
TSS using 20 ng of ChIP DNA from A2B1 and A2C12, and a
dilution line established from an MNase-digested A2C12 chro-
matin. Overall, H2A values were greater than H2A.Z; and that
A2B1 (H2A . H2A.Z) was lesser than A2C12 (H2A . H2A.Z)
(Figure S12C), in agreement with nucleosome depletion
associated with gene expression. To confirm results, we performed
independent N-ChIP with A2B1 vs. A2C12 and using Ct values as
well as Percent Input normalization to interpret results (Figure 5).
Epigenetic Silencing in Lung Cancer Cells
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H2A.Z in A2B1 vs. A2C12, we found that H2A and H2A.Z were
higher in A2C12 than in A2B1, a result suggestive of high
nucleosome occupancy in transcriptional repression.
Comparison of H2A and H2A.Z nucleosomes in lung
tumor. To determine the enrichments of H2A and H2A.Z
nucleosomes in lung tumor, we conducted N-ChIP using
chromatin isolated from two pooled solid lung tumors. Cadm1
was still expressed in the tumors (data not shown). ChIP-PCR
Figure 4. Chromatin analysis with micrococcal nuclease (MNase) to map nucleosome positions in Cadm1 promoter region.
(A) Position of five predicted nucleosomes using the Segal algorithm, the location of PCR primers used in amplifying fragments after digestion of
chromatin with MNase, and MNase-preferred sites (CATA). Fragments that were also analyzed by quantitative-PCR are boxed. (B) Quantity of
amplified fragments in different lung cancer cell lines, including two cell lines that were treated with 5-aza-dC, and a ’blind‘ control uncharacterized
cell line (AEII) which does not express Cadm1. BD10-aza in nuc2F3-1/2R3-1 is a missing value. (C) Mouse normal lung, mouse lung tumor as compared
to lung cancer cell lines, A2B1 and A2C12. The chromatin here analyzed for A2B1 and A2C12 are different from those in (B).
doi:10.1371/journal.pone.0038531.g004
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in most all primers at predicted nucleosomes along the promoter
region of Cadm1 (Figure S13). Quantitative PCR confirmed high
enrichments of both H2A and H2A.Z in lung tumor. Overall H2A
was greater than H2A.Z (Figure 5).
Comparison of H2A and H2A.Z nucleosomes in normal
lung. We compared H2A and H2A.Z in normal lung
chromatin isolated from seven pooled normal lungs of 11-
month-old, non-transgenic female mice. Normal PCR with
different primers trained at predicted nucleosomes showed the
presence of both H2A and H2A.Z, but banding intensities in
different primer pairs were higher in H2A.Z than in H2A
(Figure S14). Indeed, in some primer pairs trained at left or
right boundaries of predicted nucleosomes, only H2A.Z could
be amplified. A second independent N-ChIP similarly using
chromatin isolated from seven pooled normal lungs and qPCR,
confirmed that overall H2A.Z was higher than H2A in normal
lung (Figure 5). ChIP values showed enrichment of H2A.Z at
nuc 3 and nuc 4, the nucleosomes closest to the TSS (Figure
S14C, Figure 5). This result found in normal lung differed from
the lung cancer cell lines and lung tumors, in which overall
H2A was greater than H2A.Z.
Nucleosomes in the Cadm1 Promoter of Lung Cancer
Cells are Enriched with Histone Variants and Histone
Modifications
Besides H2A.Z, we conducted ChIP with the histone variant
H3.3, as well as the histone modifications H3K4me3 and
H3K27me3, again on A2B1 (with Cadm1 expression) and A2C12
(without Cadm1 expression). ChIP results obtained using Ct values
and Percent Input in analyzed nucleosomes in A2B1 vs. A2C12
are shown in Figure 6. For these experiments, H2A served as
control for histone integrity. As for A2B1, it showed that
enrichment of H3K4me3 and H3K27me3 was not in all
nucleosomes. Indeed, the values for these histone modifications
in nucleosomes 1 and 3 in A2B1 were higher than in A2C12.
A summary of results from different ChIP experiments showed
overall enrichments of histone variants and histone modifications
of nucleosomes along the Cadm1 promoter region in lung cancer
cells in (Figure 7B, left panel). The corresponding results on
different nucleosomes are shown in Figure S15. To determine
enrichment relative to nucleosome density, we further normalized
results relative to the canonical H2A, which was included in each
ChIP experiment with the histone variants and modifications. This
normalization method is assumed to correct for differences in
ChIP signals that are caused by differences in the density of
nucleosomes, rather than by changes in histone modification levels
[36]. Furthermore, the rationale behind normalization relative to
nucleosome density is that histone modifications can only be
detected at a specific DNA sequence region if this region is also
wrapped into nucleosomes. We found that A2C12 exhibited
higher enrichments with respect to histone variants (H2A.Z, H3.3)
and histone modifications (H3K4me3 and H3K27me3) than
A2B1 (Figure 7B, right panel).
We also analyzed ChIP data on the basis of qPCR values
obtained using 20 ng of ChIP DNA as template as well as
calibration standards from a dilution series of gel-isolated
MNase-digested chromatin of A2C12. Results confirmed overall
that H2A was higher in A2C12 than A2B1, and also showed
Figure 5. ChIP with H2A and H2A.Z in lung cancer cell lines, lung tumor, and normal lung. Results in analyzed nucleosomes are expressed
as Percent Input using Ct values. The lung cancer line A2B1 still expresses Cadm1, while A2C12 does not. For quantitative PCR, 20 ng of ChIP DNA
was used as template in all samples, including DNA obtained in normal rabbit IgG. The primer sets used and corresponding color coding are
indicated on the uppermost right hand corner.
doi:10.1371/journal.pone.0038531.g005
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higher in A2C12 than in A2B1 (Figure S16). Furthermore, we
have also undertaken normal PCR using 2 ml of ChIP DNA
and a panel of 17 primer sets involving five different
nucleosomes along the Cadm1 promoter region. We observed
higher banding intensities of PCR products obtained for H2A,
H2A.Z, H3.3, H3K4me3, and H3K27me3 in A2C12 than in
A2B1 (e.g. Figure S12). Altogether, ChIP data supported
higher nucleosome occupancy, as well as higher enrichment of
histone variants and histone modifications in A2C12 than in
A2B1. The presence of such histone variants and histone
modifications might also have an effect on nucleosome
positioning, since the use of different primer pairs to interrogate
nucleosomes especially on primers shifted to the left or right
border of nucleosome, gave more PCR products in A2C12 than
A2B1 (data not shown).
FAIRE Regions are Higher in A2B1 than in A2C12
To determine whether there is indeed more open chromatin in
A2B1 than A2C12, we adapted the FAIRE (formaldehyde-assisted
isolation of regulatory elements) method [37] to our analysis. In
this method, chromatin is crosslinked using formaldehyde,
sonicated, and subjected to phenol-chloroform extraction. DNA
fragments recovered in the aqueous phase (DNA not bound by
protein) are then sequenced. Most enriched FAIRE regions were
found near the transcription start sites (TSS), and overall there was
a positive relationship between FAIRE signals and transcript
levels. Using the FAIRE method and normal PCR using middle
primers on nuc 1, nuc 3, and nuc 4, we found higher banding
intensity in A2B1 than A2C12, and this increased towards the
TSS, and thus suggestive of more open chromatin for A2B1
(Figure 7C). Consistent with this result, the corresponding
organic phase (chromatin bound by protein) gave only products
in A2C12.
Discussion
The landscape of epigenetic silencing is complex, and although
whole-genome analysis using next-generation technologies pro-
vides insights at the level of epigenome, there is still much to learn
from functional dissection of silencing events at the promoter of
single genes. In this study, we sought to understand the epigenetic
silencing complexity in the promoter region of Cadm1 in lung
cancer progenitor cell lines established from single, spontaneously
transformed lung tumors of c-Myc and c-Raf double-transgenic
mice. Promoter hypermethylation in these cell lines correlates with
transcriptional repression. We searched for additional epigenetic
silencing events in the Cadm1 promoter and compared results with
normal lung and lung tumors. Using genomic sequence and
bioinformatic tools, we predicted nucleosome positions and
transcription factor binding sites along the Cadm1 promoter. We
carried out a rigorous single-molecule mapping of chromatin with
the DNA methyltransferase M.SssI to determine nucleosome
occupancy and occlusion of transcription factor binding sites.
With a panel of primers to interrogate the middle, left and right
borders of predicted nucleosomes, we analyzed for differential
nucleosome positioning in MNase-digested chromatin and ChIPed
DNA with canonical histone H2A, histone variants H2A.Z and
H3.3, as well as for histone modifications, H3K4me3 and
H3K27me3. Overall, the present investigation defines a landscape
of silencing characterized by high nucleosome occupancy,
nucleosome sliding, DNA methylation, and enrichment of histone
Figure 6. ChIP with histone variant (H3.3) and histone modifications (H3K4me3, H3K27me3) in lung cancer cells. ChIP experiments
were undertaken in a lung cancer cell line with (A2B1) and without (A2C12) Cadm1 gene expression. Results on different nucleosomes are expressed
as Percent Input using Ct values. For quantitative PCR, template was adjusted to 20 ng for all samples, including DNA obtained in normal rabbit IgG.
The primer sets used and corresponding color coding are indicated on the uppermost right hand corner.
doi:10.1371/journal.pone.0038531.g006
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PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e38531Figure 7. Chromatin status in repressed promoter of Cadm1 in lung cancer cells. (A) Annotations of analyzed promoter region of Cadm1,
showing location of CpGs, transcription factor binding sites, predicted nucleosome positions with different algorithms, and primers used in
amplifying different fragments. Enclosed are positions of fragments analyzed by qPCR. (B) Comparison of total ChIPed DNA from different
experiments with a canonical histone (H2A), histone variants (H3.3, H2A.Z) and histone modifications (H3K4me3, H3K27me3), in a lung cancer cell line
with (A2B1) and without (A2C12) Cadm1 gene expression. ChIP results are expressed as Percent Input using Ct values (left panel) and as further
normalized relative to H2A (right panel). Normalization relative to H2A was undertaken at the level of nucleosomes in each experiment. (C) Amplified
fragments in three different lung cancer cell lines after FAIRE method, i.e. formaldehyde crosslinking of chromatin and recovery of DNA fragments not
bound by protein in the aqueous phase (boxed). The recovered DNA in the corresponding organic phase is also shown. In the aqueous phase (=open
chromatin), banding intensity of amplified fragments in the cell line with Cadm1 gene expression (A2B1) was higher than in the two cell lines without
gene expression (GA7, A2C12). In the organic phase (=bound chromatin), fragments were only amplified in A2C12. Both positive control (A2C12
genomic DNA) and negative control (No DNA) for PCR are included during the analysis.
doi:10.1371/journal.pone.0038531.g007
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H3K4me3 and H3K27me3, which all colocalize at the same
nucleosome positions.
Whether intrinsic DNA sequence preferences have a major role
in determining the organization of nucleosomes in vivo is a subject
of scientific debate [38,39]). The discussion stems from contrasting
findings in yeast after comparing positions of nucleosomes
reconstituted in vitro to a map of in vivo locations. A recent study
based on reconstituted nucleosome positioning in yeast also argued
against a DNA-intrinsic or transcription-based mechanism for
organizing nucleosomes around the 59 ends of genes, but rather
positioning appears to be driven by ATP-dependent activities that
package nucleosomes against a 59 barrier [40]. Our primary
interest in using nucleosome positioning prediction algorithms
based on genomic DNA sequence was to facilitate our analysis,
and to streamline the design of primers to interrogate the
chromatin state in normal and lung cancer cells. Nonetheless,
we found that sequences within predicted nucleosome positions
(i.e. nucleosome core sequences) could be amplified after MNase
digestion and/or ChIP analysis with histone antibodies specifically
H2A, using native or crosslinked chromatin. Furthermore, CpGs
within these predicted nucleosomes showed protection after
treatment of chromatin with the DNA methyltransferase, M.SssI
to suggest nucleosome occupancy.
Thus, the five analyzed nucleosomes as predicted using the
algorithm from the Segal lab and described in several papers (e.g.
[41]) are also formed in vivo. However, we observed possible
alternative positioning of nucleosomes, in which we obtained in
MNase-digested chromatin and ChIP-DNA a 125-bp or a 101-bp
fragment that encompasses the supposed to be linker after nuc 4
and a part of nuc 5 (see Figures S10, S11, S12, S13, S14).
Furthermore, differences in nucleosome borders in both normal
and lung cancer cells were also found which may be attributed to
the presence of modifying factors of nucleosome positions (see
Introduction). Our results suggest that while DNA sequence
influences the formation of nucleosome organization in vivo,
sequence-dependent nucleosome positioning is probably not the
sole determinant of chromatin organization.
Single-molecule chromatin mapping with M.SssI showed high
nucleosome occupancy in the lung cancer cell lines associated with
promoter hypermethylation and transcriptional silencing. The
nucleosomes in the region where transcription factor binding sites
are located and near the transcriptional start site (TSS) were
evicted after treatment with the demethylating agent, 5-aza-dC
and was accompanied by slight re-expression of the gene.
Furthermore, high nucleosome occupancy can be confirmed by
the higher levels of ChIPed H2A in lung cancer cell lines with little
or no Cadm1 gene expression, than in a cell line that still expresses
the gene, as obtained in native and in formaldehyde-crosslinked
chromatin. These findings are similar to those obtained in the
bidirectional MLH1 promoter CpG island, in which three
nucleosomes, almost completely absent from the three start sites
in normal cells, were present on the methylated and silenced
promoter of cancer cells [30]. They also observed that upon
recovery of gene expression with 5-aza-dC, these nucleosomes
were removed from the promoter molecules. High nucleosome
occupancy suggests a tight or closed chromatin structure, and
DNA methylation may have contributed to this configuration by
increasing nucleosome compaction and rigidity [13].
The MNase chromatin analysis in different lung cancer cell
lines, lung tumor and normal lung supports the formation of the
analyzed nucleosomes along the promoter region of Cadm1.I n
agreement of sequences located at the nucleosome core, the
quantity of PCR products of primers designed inside predicted
nucleosomes was higher than those that interrogate nucleosome
borders. Nonetheless, there were differences among the lung
cancer cell lines. The quantity of qPCR product after MNase
digestion seems to correlate with gene expression and the degree of
methylation, i.e. those cell lines with gene expression have higher
qPCR values than those repressed and highly methylated. Overall,
highest amplification efficiency was observed in normal lung, then
in lung tumor, and followed by the lung cancer cell lines. Similar
findings have been demonstrated in maize gene, ZmMI1 in which
the correlation of methylation status with the nucleosomal
structure was analyzed after MNase digestion of chromatin [42].
Chromatin analysis with MNase can reveal nucleosomal nature
of DNA, but it has its own bias and thus requires control [43].
MNase has sequence preference; it cuts DNA primarily at runs of
alternating dA and dT that are preceded by dG or dC. For
example, CATA is a favored site, but a CATA site will be resistant
to cleavage if located inside a nucleosome. Our analysis showed
that MNase digestion of ‘naked’ genomic DNA did not yield the
expected PCR products. In chromatin samples, a CATA site
inside a nucleosome (nuc 1, Figure S2) did not lead to digestion
suggestive of nucleosomal DNA being amplified. Furthermore,
independent MNase digestions, including formaldehyde-cross-
linked chromatin, in a lung cancer cell line, yielded expected
PCR products (data not shown). Finally, ChIP results obtained
with native chromatin coupled with MNase digestion could be
confirmed with sonicated formaldehyde-crosslinked chromatin,
and single-molecule mapping with DNA methyltransferase.
Notably, in normal lung H2A-containing nucleosomes especial-
ly near the transcription start site (TSS) were depleted. Similarly,
the M.SssI map of normal lung also showed absence of
nucleosomes around the TSS in most clones, but instead
transcription factors binding, e.g. Sp1. These observations provide
further evidence that the region immediately upstream of the TSS
of active genes is depleted of stable nucleosomes to allow binding
of the transcriptional machinery to the DNA. This region is
referred to as nucleosome-depleted region (NDR) or nucleosome-
free region (NFR) in yeast promoters [44]. The NFR is defined as
approximately 150 bp region that is devoid of nucleosomes and
occurs at about 200 bp from the translation start site (ATG), and
enriched with transcription factor binding sites and poly-
deoxyadenosine or poly-deoxythymidine sequences. A question
was raised regarding the term ‘NFR’ because certain types of
nucleosomes were found unstable and underrepresented around
the TSS, depending on the salt concentration used during
chromatin isolation [45]. Our data presented here are based on
chromatin isolated at high salt concentration (140 mM NaCl).
We also found in normal lung that H2A.Z binding correlated
with active transcription, in which nucleosomes upstream and
downstream of TSS in Cadm1 promoter were enriched with
H2A.Z. Indeed, H2A.Z was much higher than H2A in
nucleosomes most adjacent to the TSS and ATG e.g. at nuc 3
and nuc 4 (2417 to –271 and 2230 to 284 relative to ATG,
respectively), and in the region where transcription factor binding
sites are located. This finding in normal lung agrees with previous
observations that H2A.Z is enriched in nucleosomes around the
TSS of genes. In yeast, H2A.Z-nucleosomes flank one or both
sides of the NFR that contains the TSS [46], while in human
genome H2A.Z is highly enriched at promoter regions in both
upstream and downstream of TSS [47]. Furthermore, in human
T cells, H2A.Z-containing and modified nucleosomes are prefer-
entially lost from the 21 nucleosome, relative to TSS [48].
We found further in normal lung that, H2A and H2A.Z-
containing nucleosomes occupy the same DNA sequence, but
H2A.Z appeared to differ from H2A as regards nucleosome
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aries, we obtained differential amplification of H2A and H2A.Z, in
which certain primers gave only product for H2A.Z to imply
different nucleosome positioning in the presence of H2A.Z. There
is suggestion that replacement of H2A with H2A.Z in specific
nucleosomes may result in the sliding of nucleosomes to different
positions [20]. Indeed, there is evidence that incorporation of
H2A.Z into promoter chromatin would allow nucleosomes to
adopt preferential positions along the DNA translational axis, a
condition that is permissive to the recruitment of the general
transcriptional machinery [49]. Furthermore, it has been shown
that H2A.Z-containing +1 nucleosomes of active genes shift
upstream to occupy TSSs during mitosis, significantly reducing
nucleosome-depleted region [50]. This mitotic shifting is specific to
active genes that are silenced during mitosis and, thus, is not seen
on promoters, which are silenced by methylation or mitotically
expressed genes.
In lung tumor, the levels of H2A and H2A.Z did not vary much;
nevertheless H2A was higher in quantity. In the two lung cancer
cell lines with repressed Cadm1 gene expression, H2A was also
higher than H2A.Z. The higher values for H2A that correlated
with transcriptional repression, suggest non-depletion of nucleo-
somes, and in agreement of a silent chromatin state. Interestingly,
the lung cancer cell line (A2C12) without gene expression
displayed higher values for both H2A and H2A.Z, than the cell
line (A2B1) that still expresses the gene, to indicate certain
depletion of nucleosomes in A2B1 than in A2C12. Indeed, the
FAIRE results support more open chromatin for A2B1 than
A2C12. Furthermore, primers to interrogate nucleosome borders
likewise amplified H2A and H2A.Z fragments in A2C12, but no
longer in A2B1 to reflect not only non-depletion of nucleosomes
but altered nucleosome positioning as well. To summarize,
H2A.Z-nucleosome occupancy was observed in both active and
silent transcriptions, but enrichment levels was highest in normal
lung and lowest in the lung cancer cell lines that displayed
promoter hypermethylation.
Although H2A.Z has been extensively studied, its exact role in
gene regulation remains unclear, being associated with both active
and repressed states of gene expression. In yeast, H2A.Z was found
to mark the 59 ends of both active and inactive genes in
euchromatin [46]. In ES cells, similar association of H2A.Z
enrichment to both states of gene expression was likewise observed
[51]. Genome-wide analysis of H2A.Z showed occupancy at
promoters of a large set of silent developmental genes, in a manner
similar to Polycomb group (PcG) proteins, which are known as
transcriptional repressors. Conversely, H2A.Z enrichment was
detected at active genes in multipotent neural precursors.
Furthermore, in reconstituted nucleosomes, H2A.Z was shown
to inhibit transcription [52]. To reconcile the positive and negative
roles of histone H2A.Z in gene expression, and along with the
observation that H2A.Z incorporation within a nucleosome leads
to repositioning of a subset of nucleosomes to a position, it has
been postulated that depending on where nucleosomes are
repositioned, positive or negative effects on gene expression could
be observed [53].
It has been demonstrated that the histone H2A.Z and DNA
methylation are mutually antagonistic chromatin marks, in
A. thaliana [54], and in puffer fish [55]. Similar relationship was
also observed in mammals using a mouse B-cell lymphoma model,
where chromatin states can be monitored during tumorigenesis
[56]. H2A.Z and DNA methylation were found to be generally
anti-correlated around TSS in both wild-type and Myc-trans-
formed cells. Furthermore, there was progressive depletion of
H2A.Z around TSS during Myc-induced transformation of pre-B
cells and, subsequently during lymphomagenesis. In our study, this
relationship seems also to hold true since H2A.Z occupancy was
found highest in normal lung which did not display DNA
methylation in the promoter region of Cadm1, and this became
less in the hypermethylated lung cancer cell lines.
In the lung cancer cell lines, we found colocalization of two
histone variants (H3.3 and H2A.Z) and histone modifications
(H3K4me3 and H3K27me3) in the same nucleosome positions in
the promoter region of Cadm1. This result may be a reflection of
single histone variants or modifications affecting single nucleo-
somes within a cell line, but combinations in the same nucleosome
within a cell are not unlikely. Indeed, different histone combina-
tions can occur with structural or functional consequences. For
instance, a single octameric nucleosome can contain two H2A.Z
histones (homotypic) or one H2A.Z and one canonical H2A
(heterotypic), and such homotypic nucleosomes were found to be
enriched and heterotypic nucleosomes were depleted downstream
of active promoters and intron-exon junctions [57]. H2A.Z and
H3.3 double variant nucleosomes can also affect nucleosome
positioning, either creating new positions or altering the relative
occupancy of the existing nucleosome position space, while only
H2A.Z-containing nucleosomes exhibited altered linker histone
binding [58]. In human cells, the H2A.Z and H3.3 double variant-
containing nucleosomes mark ‘nucleosome-free’ regions of active
promoters as well as other regulatory regions, such as enhancer
and insulators [35]. These double variants are unstable and are
lost in the preparative methods usually used in studying
nucleosome structure, and this instability facilitates the access of
transcription factors to promoters and other regulatory sites in
vivo. Moreover, H2A-Z containing promoters also contain mono,
di, trimethylated K4H3, in which H2A.Z-deposition or H3K4me3
modification may facilitate eviction or repositioning in the
promoter regions of the human genome [48].
Deregulation of H3K4me3 and H3K27me3, which are
catalyzed by tri-thorax-group (trxG) proteins and polycomb-group
(PcG) proteins, respectively is associated with cancer development
[59]. Nucleosomes containing histone modification H3K4me3
have been associated with active transcription, while those with
H3K27me3, with transcriptional repression. Thus, for us to
observe enrichment or depletion concerning these opposing
histone marks in lung cancer lines with different transcriptional
status was not unexpected. However, H3K4me3 and H3K27me3
both colocalized, together with the histone variants H2A.Z and
H3.3, in the same nucleosome positions. Nevertheless, in contrast
to the lung cancer cell lines A2C12 (without Cadm1 gene
expression), only low levels of H3K4me3 and H3K27me3 were
observed in A2B1 (with Cadm1 gene expression), and when
detected these could only be amplified in not all nucleosomes (i.e.
so far, in nuc 1 and nuc 3 (21011 to 2865 and 2417 to 2271
relative to ATG, respectively).
The colocalization of H3K4me3 and H3K27me3 in the Cadm1
promoter in lung cancer progenitor cells is similar to observations
made in embryonic stem cells as will be described below, and such
given dual marks is associated with epigenetic plasticity of these
cells. Several genome-wide maps of H3K4me3 and H3K27me3
notably in embryonic stem (ES) cells provide evidence of genes
exhibiting ‘‘bivalent domains’’ associated with both histone
modifications [60–63]. These bivalent domains that combine both
the ‘‘repressive’’ and ‘‘activating’’ modifications are associated
with transcriptional repression, to poise genes prior to activation or
to stably repress genes during differentiation.
For example, in mouse embryonic stem cells, neural progenitor
cells and embryonic fibroblasts, the relative levels of H3K4me3
and H3K27me3 modifications in promoter regions can be used
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expression, or stably repressed [61]. In human embryonic stem
cells, colocalization of H3K4me3 and H3K27me3 on the same
promoters was found to be a rule rather than an exception [62].
This bivalent histone modification was not restricted to early
developmental genes in ES cells to keep cells poised for activation,
but also to pluripotency-associated genes that become repressed
during differentiation.
Bivalent configurations were also observed in T-cells. Global
mapping of H3K4me3 and H3K27me3 in differentiating lineages
of mouse CD4
+ T cells revealed a broad spectrum of epigenetic
modification states of genes, contributing to specificity as well as
plasticity in lineage fate determination [64]. Among these include
the marking of both H3K4me3 and H3K27me3 in the promoter
regions of the genes encoding for transcription factors Tbx1 and
Gata3 in non-expressing lineages. Similarly, genome-wide analysis
of histone methylation H3K4me3 and H3K27me3 and expression
profiles in naı ¨ve and memory CD8
+ T cells showed that
correlation exists between gene expression and the amounts of
H3K4me3 (positive correlation) and H3K27me3 (negative corre-
lation) across the gene body [65].
Indeed, there are studies documenting bivalent domains
involving H3K4me3 and H3K27me3 in cancer cells and response
to epigenetic drug treatments [66,67]. For example, transcription-
al repression of DACT3, which is an epigenetic regulator of Wnt/
b-catenin signaling in colorectal cancer, was not associated with
CpG promoter methylation, but the presence of the bivalent
histone modifications H3K4me3 and H3K27me3 in colon cancer
cells [66]. This repression could be reversed with the combined use
of S-adenosylhomocysteine hydroxylase inhibitor 3-deazanepla-
nocin A (DZNep) and histone deacetylase inhibitor trichostatin A
(TSA), but not the combination of DNMT inhibitor 5-AzaC and
DZNep or TSA. Another study in colon cancer cells demonstrated
that bivalent domains also mark the promoters of genes that
become DNA methylated in adult tumor cells to enforce
transcriptional silencing [67]. Analysis of neighboring genes,
including many frequently silenced in colon cancer cells, in a
chromosomal region at 5q35.2 spanning 1.25 Mb showed that
inactive domains are defined by low transcriptional rates,
promoter DNA methylation, and the presence of bivalent histone
marks, H3K4me3 and H3K27me3. Transcriptional up-regulation
accompanied by full or partial DNA demethylation was observed
in genes containing bivalent domains and methylated promoter
CpG islands after 5-aza-dC or combined 5-aza-dC/TSA treat-
ments, but not TSA alone. Lastly, in addition to bivalent histone
modifications of H3K4me3 and H3K27me3, frequent promoter
colocalization of transcriptionally opposing bi-, tri, and tetra-
valent histone marks has been demonstrated to confer microen-
vironment-responsive epigenetic plasticity to ovarian cancer cells
[68].
Our study may provide some mechanistic insights for follow-up
investigations towards the regulation of Cadm1 and its role in lung
cancer. We have shown colocalization of canonical histone H2A
with histone variants (H2A.Z, H3.3), and histone modifications
(H3K4me3, H3K27me3) in same DNA sequence, which likewise
exhibited heavy CpG methylation. The lung cancer cell line which
did not express Cadm1 (A2C12) exhibited higher values for these
epigenetic modifications, and most likely that their presence
contributed jointly or in parallel in the silencing of the gene.
Indeed, CpG methylation can have a distinct influence on protein
binding when it is present within a nucleosomal background.
SILAC nucleosome affinity purifications (SNAP) identified pro-
teins whose binding to nucleosomes is regulated by CpG
methylation and histone modification H3K4me3, H3K9me3,
H3K27me3 or their combination [18]. Among these proteins
include, for instance, the origin recognition complex (ORC),
which was identified to be methylation-sensitive nucleosome
interactor and recruited cooperatively by DNA and histone
methylation. Their results also showed PAX6 to be nucleosome
interactor as well in the presence of both methylated CpGs and
histone modifications. PAX6 belongs to the paired-box (PAX)
gene family of transcription factors involved in normal develop-
ment and disease. PAX genes are frequently expressed in cancer,
and that endogenous PAX gene expression is required for the
growth and survival of cancer cells [69]. It is tempting to speculate
about the role of PAX6 in the lung cancer line A2C12, and
whether this factor was also recruited. In the Cadm1 promoter, a
putative PAX6 binding site is within a nucleosomal DNA (nuc 3,
CpG site 2350, relative to ATG). In A2C12, the nuc 3 region is
enriched with histone modifications H3K4me3 and H3K27me3,
and the CpGs are heavily methylated. In the M.SssI map of
normal lung in clones where no apparent nucleosomes were
present, the CpG within the core binding site of PAX6 was not
protected to suggest no binding occurred.
Furthermore, M.SssI maps and EMSA experiments suggested
that PPARg might be binding to the Cadm1 promoter in a lung
cancer cell line (A2C12), but not in normal lung. Mutated binding
sequence or 100x competition with a normal probe abolished this
binding. PPARg’s binding to the putative site was observed in
A2C12 nuclear extracts, of both untreated and treated with 5-aza-
2dC. Peroxisome proliferator-activated receptors (PPAR)-g be-
longs to the nuclear hormone receptor superfamily of ligand-
dependent transcription factors and may be relevant for lung
cancer therapy (see review, [70]). PPARg is expressed in human
lung cancer cell lines (both SCLC and NSCLC), and its expression
in lung cancer patients correlates with differentiation status and
survival. Furthermore, PPARg ligands have been shown to inhibit
tumor growth and progression in preclinical models of lung
cancer, by modulating various cellular processes in cancer cells,
stromal cells and tumor microenvironment, through PPARg
crosstalk with other signaling pathways. Whether PPARg binding
could have contributed to the regulation of Cadm1 in A2C12 lung
cancer cell line, or have implications at all in the use of PPARg
ligands, remains to be explored. The PPARg putative binding site
is located at the left border (adjacent) of a nucleosome (nuc 3)
which can be easily influenced not only by DNA methylation but
by nucleosome sliding as well.
Taken together, we have employed several approaches in
dissecting epigenetic silencing complexity in the promoter region
of the tumor suppressor gene Cadm1 in mouse lung cancer
progenitor cells. Knowledge gained would help understand how
different epigenetic landscapes contribute to lung tumorigenesis
and response to epigenetic drug treatments. First of all, the CpGs
in the promoter region of Cadm1 exhibited DNA methylation and
this promoter hypermethylation correlated with transcriptional
repression of the gene. DNA methylation was heterogeneous
within and among the different lung cancer cell lines. Mapping of
chromatin in single promoters revealed high nucleosome occu-
pancy associated with silencing, indicative of a compact chromatin
structure that is refractory to nucleosome remodelling and
dynamism necessary for active transcription. Indeed, in contrast
to normal lung, nucleosomes were present especially in regions
where transcription factor binding sites are located. More
important, although high nucleosome occupancy was a common
characteristic of silent promoters, chromatin maps showed
heterogeneity within and among the different lung cancer cell
lines. Moreover, chromatin analysis with micrococcal nuclease
(MNase) suggested differential nucleosome positioning in the lung
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transcription factors found at the boundaries of nucleosomes.
Chromatin immunoprecipitation (ChIP) with histone variants and
histone modifications also showed differences in nucleosome
boundaries in two lung cancer lines that differed in Cadm1 gene
expression. In a lung cancer cell line with no Cadm1 gene
expression, there was colocalization of histone variants (H2A.Z,
H3.3) that when present as double-variant affects nucleosome
stability and positioning, as well as histone modifications in which
one is an activating mark (H3K4me3) and the other is a repressive
mark (H3K27me3) in the same nucleosome position. There is
likelihood of several combinatorial possibilities that could affect
nucleosome structure and positioning, which in turn have
implications in the binding of transcriptional machinery and
chromatin remodelling proteins to the DNA. The presence of both
activating (H3K4me3) and repressing histone modifications
(H3K27me3) known as ‘bivalent’ marks suggests stem-cell features
of the lung cancer cells. In conclusion, there is complexity in the
landscape of epigenetic silencing which is defined not by single but
by the combinations of several epigenetic events, thereby
rendering varying response to epigenetic drugs.
Materials and Methods
Lung Cancer Cell Lines, Lung Tumors and Normal Lungs
We analyzed chromatin from lung cancer cell lines, solid lung
tumors, and normal lungs from mice. The 10 lung cancer cell lines
of transgenic c-Raf/c-Myc mice have been described previously
[29]. The lung tumors were of c-Raf transgenic mice [71], while
the normal lungs of non-transgenic mice. Chromatin of each cell
line was investigated separately, but pooled chromatin from 2–3
lung tumors, or 7–9 normal lungs were used for different
investigations.
The transgenic mice were established many years ago according
to an approved protocol (33-42502-02/548) by the Lower Saxony
State Office for Consumer Protection and Food Safety (Germany).
The lung cancer cell lines from the transgenic mice were also
established according to an approved protocol (33-42502-02/548)
by the Lower Saxony State Office for Consumer Protection and
Food Safety (Germany). The normal lungs were from non-
transgenic mice obtained from the Charles River Laboratories.
Sectioning was undertaken by a trained scientist and registered at
the regulatory office (33.42502/2) to carry-out animal experi-
ments. The maintenance of animal models used in this study is
carried out in strict accordance to regulations of care and use of
laboratory animals by the same regulatory office.
Bioinformatic Predictions
Different bioinformatic tools were utilized to predict nucleo-
some positions along the promoter region of Cadm1, which are
based primarily on nucleosome positioning encoded in the DNA
sequence. The online nucleosome prediction by genomic sequence
(http://genie.weizmann.ac.il/software/nucleoprediction.html)
from the Segal lab described in several papers [41,72,73] is based
on the notion that DNA sequence is highly predictive of
nucleosome positioning, and that certain sequences such as poly
(dA:dT ) tracts are strongly disfavored by nucleosomes. The
NuPoP: Nucleosome Positioning Prediction Engine (http://
nucleosome.stats.northwestern.edu/) [74], predicts nucleosome
positioning using a Hidden Markov Model by explicitly modeling
the linker DNA length. The ICM Web (http://dna.ccs.tulane.
edu/icm/) [75] allows the users to rapidly assess nucleosome
stability and fold sequences of DNA into putative chromatin
templates. Using TRANSFAC (http://www.gene-regulation.
com/pub/databases.html), we analyzed putative binding sites of
transcription factors in the promoter region of Cadm1.
Primer Sequences
PCR primers to analyze the Cadm1 promoter region in bisulfite-
treated genomic DNA in mice were reported earlier [29]. PCR
primers used during MNase and ChIP analyses are given in
Table S2. These primers were designed based on predicted
nucleosomes from the Segal lab algorithm. The PCR products of
different primer combinations ranging from 66–222 bp, and
location on the Cadm1 promoter region are described in Table
S3. Specificity of PCR primers were validated by sequencing of
amplified fragments in mouse genomic DNA as well as in ChIP
DNA, and 100% homology to a reference sequence (AC121870.2
within nt 161329–162348). The same primer pairs were also used
to determine sequence alterations of the promoter region in
different lung cancer cell lines.
Gene Expression Analysis
Total RNA was isolated from frozen mouse lung tissues or cell
lines with RNeasy Mini kit, and reverse transcription–PCR (RT-
PCR) was undertaken with Omniscript RT kit (Qiagen). Semi-
quantitative RT-PCR was performed using Thermostart Taq
polymerase (ABgene) on T3 thermocyclers (Biometra), whereas
quantitative RT-PCR on Light Cycler (Roche) using Absolute
qPCR Sybr Green Capillary (ThermoFisher). Typically, 25 to
50 ng of cDNA were used for template. Reaction components and
cycling variables were according to standard procedure.
Analysis of Bisulfite-treated Genomic DNA
Genomic DNA was isolated in tissue samples and cell lines using
Nucleo Spin Tissue (Macherey-Nagel). Bisulfite treatment was
undertaken with EpiTect Bisulfite kit (Qiagen) using manufactur-
er’s instructions. Primers for methylation assays were designed
with MethPrimer (http://www.urogene.org/methprimer/index1.
html). PCR fragments were directly sequenced using BigDyeTer-
minator v3.1 kit and ABI 3100 Genetic Analyzer (Applied
Biosystems), or PCR fragments were cloned using TOPO TA
Cloning kit (Invitrogen) before sequencing. Sequences were
analyzed using SeqMan (Lasergene 7.0) and confirmed by BISMA
analysis (http://biochem.jacobs-university.de/BDPC). During
BISMA scoring, the CpGs within the primer sequences (i.e.in
fragments MFR1, MFRA, TSFR1) were not included.
5-Aza-2-deoxycytidine Treatment of Cells
Cells (1610
6) seeded in T25 cell culture flasks containing 5 mL
of DMEM with 10% FCS, 2x L-glutamine, and 2x penicillin/
streptomycin. Cells were cultured 48 h, treated with fresh 2 mmol/
L 5-aza-2-deoxycytidine (5-aza-dC; Sigma) dissolved in medium
for 3 d, and allowed to recover for 2 d.
Chromatin Isolation
For lung cancer cell lines, approximately 1610
6 cells were
grown 2–3 d until about 100% confluency, pelleted, and washed
twice with 1 mL cold PBS. Cell pellet was resuspended completely
in 300 mL lysis buffer (NPB: 10 mM Tris-HCl pH 7.4, 2 mM
MgCl2, 140 mM NaCl, plus 0.5% Triton X-100), supplemented
with protease inhibitors consisting of 40 mM beta-glycerophos-
phate, 4 mM pefabloc, 1 mM sodium orthovanadate, 1 mM
DTT, and 1x Complete
TM Protease Inhibitor Cocktail (Roche).
After 10 min incubation and the control of nuclei quality by
microscopy, homogenate was carefully layered onto 400 mL1V /
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14000 rpm to pellet nuclei for further experiments.
For normal lungs and lung tumors, fresh tissues were weighed
and cut into small pieces. Pre-chilled homogenization buffer
(10 mL/g tissue) was added to the samples, and cells were
disrupted using a Potter homogenizer. The homogenization buffer
(2.2 M sucrose, 10% glycerine, 10 mM Hepes pH 7.6, 15 mM
KCl, 1 mM EDTA) was supplemented with protease inhibitors
consisting of 40 mM beta-glycerophosphate, 1 mM sodium
orthovanadate, 1 mM DTT, 1x Complete
TM Protease Inhibitor
Cocktail (Roche), 0.15 mM spermine, and 0.5 mM spermidine.
Homogenates were transferred into ultracentrifuge tubes and
centrifuged for 60 min, 24000 rpm at 2uC (Beckmann Coulter
Optima
TM LE-80K, SW28.1 or SW32 Ti rotor). After aspirating
most of the supernatant, 1 mL of NPB plus 0.5% Triton X-100
and protease inhibitors was added, transferred onto 500 mL1V /
V 50% sucrose/NPB bed, and centrifuged at 10 min 4uC
14000 rpm to pellet nuclei for further experiments.
M.SssI Treatment of Chromatin
The nuclei pellet from chromatin isolation was washed with
100 mL1 xM.SssI buffer (NEB, 10 mM Tris–HCl pH 7.9, 50 mM
NaCl, 10 mM MgCl2, 1 mM DTT). The nuclei pellet was
incubated in 150 mL reaction volume containing 60 U M.SssI,
160 mM S-adenosylmethionine (SAM) and 1x M.SssI buffer, for
20 min at 37uC, centrifuged to remove supernatant, and
proceeded immediately to DNA isolation with Nucleospin Tissue
Kit (Macherey-Nagel). As ‘naked’ control, 1 mg mouse genomic
DNA was treated with 60 U of M.SssI. Genomic DNA was
bisulfite-treated for methylation analysis.
MNase Digestion of Chromatin
The nuclei pellet from chromatin isolation was washed with
100 mL 1x MNase buffer (NEB, 50 mM Tris-HCl 5 mM CaCl2).
The nuclei pellet was incubated in 250 mL reaction volume
containing 60 U MNase (NEB, 0.3 mL of 2000 Gel Units) 1x
MNase buffer, and 1x BSA for 15 min at 25uC. The reaction was
centrifuged to remove supernatant, and proceeded immediately to
a modified DNA isolation with Nucleospin Tissue Kit (Macherey-
Nagel). Briefly, pellet was resuspended in 200 mL Buffer T1. After
adding 25 mL Proteinase K solution (20 mg/mL) and 200 mL Buffer
B3, reaction was incubated at 70uC for at least 15 min. DNA was
extracted with phenol-chloroform:isoamyl alcohol (25:24:1), dis-
solved in 100 mL Elution buffer (Macherey-Nagel), and incubated
with 3 mL of RNase A (10 mg/mL) for 1 h 37uC. The resulting
fragments of about 150–200 bp were gel-isolated, amplified with
nucleosome-trained primers, or directly used for ChIP. As control,
a parallel digestion of ‘naked’ genomic DNA was undertaken. As
template, 2 mL of isolated DNA for normal PCR, while 20 ng for
qPCR was used.
Chromatin Immunoprecipitation (ChIP)
ChIP experiments on histones were mostly carried out with N-
ChIP, which uses native chromatin. In contrast, X-ChIP uses
chromatin in which DNA and proteins are crosslinked usually with
formaldehyde. For the N-ChIP, chromatin from the lung cancer
cell lines and lung tissues were isolated and digested with MNase
resulting mostly in about 150–200 bp fragments. For ChIP,
MNase digestion was stopped by adding 5 mL of 0.5M EDTA
(10 mM final concentration). The steps for primary antibody-
DynabeadsH coupling, binding of chromatin to the beads, and
washing were essentially according to suggested protocol (MAG-
nify
TM Chromatin Immunoprecipitation System, Invitrogen), and
buffers [76]. After washing, bead pellets were resuspended in a
final volume of 200 mL Buffer T1 (Macherey-Nagel) and
proceeded to DNA isolation steps described under MNase
digestion of chromatin. A parallel ChIP with formaldehyde-
crosslinked chromatin was carried out with H2A on some lung
cancer cell lines. The X-ChIP procedure was as essentially
described previously [77] (see Methods S1).
Antibodies
Histone antibodies were obtained from Abcam: H2A (ab18255),
H2A.Z (ab4174, ab18263), H3.3 (ab62642), H3K4me3 (ab1012),
and H3K27me3 (ab6002). The normal rabbit IgG antibody was
from Sta. Cruz Biotechnology (sc-2027). Generally, 5 mgo f
antibody was used for each ChIP experiment.
ChIP-PCR and Analysis of Data
Both normal PCR and quantitative PCR (qPCR) were
undertaken to analyze ChIP-DNA. For normal PCR, template
was 2–5 mL of 100 mL eluted ChIP-DNA. For qPCR, template
(ChIP samples and Input DNA) was adjusted to 20 ng. When
DNA was detected in IgG controls, 20 ng of DNA was also used
for qPCR and included in the analysis. Calibration standard for
qPCR consisted of a dilution series of gel-isolated MNase-digested
chromatin from a lung cancer cell line (A2C12). At least three
independent ChIP experiments were undertaken when feasible.
The qPCR data are given as non-normalized values as obtained
by fit point algorithm on the Light Cycler (Roche), and with
adjusted PCR template of 20 ng for all samples, and/or Percent
Input values based on 1% of starting chromatin and Ct values.
Supporting Information
Figure S1 M.SssI maps in controls, normal lung, and
lung tumor. (A) Location of the five fragments analyzed in the
Cadm1 promoter region that cover 69 CpGs 2944 to +41, relative
to the translation start site, ATG. CpGs are represented by stripes.
The maps (B–E) were obtained with BISMA (http://biochem.
jacobs-university.de/BDPC/), where blue boxes representing
unmethylated CpGs (=protected) while red boxes, methylated
CpGs. The fragments are presented with respect to their location
i.e. from BFR to TSFR1. In lung tumors and lung cancer cell lines,
CpG methylation could be endogenous and/or from the M.SssI
treatment. A2C12 is a lung cancer cell line that does not express
Cadm1 and showed prior CpG methylation. The CpGs in the core
sequence of Sp1 and Zf5 binding sites are indicated by arrows.
(TIF)
Figure S2 M.SssI maps in normal lung, lung tumor and
lung cancer cell lines in CpGs within the BFR fragment
(255 bp, 6 CpGs 2944 to 2837). (A) Annotation of the BFR
fragment showing the CpGs, predicted nucleosomes with the
Segal, ICM, NuPOP algorithms, and two MNase-preferred
(CATA) restriction sites. The maps (B–D) were obtained with
BISMA where blue boxes representing unmethylated CpGs
(=protected) while red boxes, methylated CpGs. In lung tumors
and lung cancer cell lines, CpG methylation could be endogenous
and/or from the M.SssI treatment. (B–C) In normal lung and lung
tumor, the CpGs within a predicted nucleosome (e.g. nuc 1) were
unmethylated to suggest nucleosome occupancy. (D) The
methylation patterns in 104 clones from 7 lung cancer cell lines
with little or no Cadm1 gene expression. Several clones likewise
exhibited same stretch of unmethylated CpGs, to also suggest
nucleosome occupancy.
(TIF)
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lung cancer cell lines in CpGs within the 1FR fragment
(279 bp, 10 CpGs, 2682 to 2531. (A) Annotation of the 1FR
fragment showing the CpGs, predicted nucleosomes with the
Segal, ICM, NuPOP algorithms, and putative binding sites of
lung-specific transcription factors (GR, NKX2-1). The maps (B–
D) were obtained with BISMA, where blue boxes representing
unmethylated CpGs (=protected) while red boxes, methylated
CpGs. In lung tumors and lung cancer cell lines, CpG methylation
could be endogenous and/or from the M.SssI treatment. (B–C) In
normal lung and lung tumor, several clones show a stretch of
unmethylated CpGs within a predicted nucleosome (e.g. nuc 2) to
suggest nucleosome occupancy. (D) The methylation patterns in
108 clones from 7 lung cancer cell lines with little or no Cadm1
gene expression. Some clones exhibited same stretch of unmethy-
lated CpGs, to also suggest nucleosome occupancy.
(TIF)
Figure S4 M.SssI maps in normal lung, lung tumor and
lung cancer cell lines in CpGs within the MFR1 fragment
(124 bp, 14 CpGs, 2456 to 2341). (A) Annotation of the
MFR1 fragment showing the CpGs, predicted nucleosomes with
the Segal, ICM, NuPOP algorithms, and putative binding sites of
transcription factors (SP3, PPARg, ER, ETF). The maps (B–D)
were obtained with BISMA where blue boxes representing
unmethylated CpGs (=protected) while red boxes, methylated
CpGs. In lung tumors and lung cancer cell lines, CpG methylation
could be endogenous and/or from the M.SssI treatment. Fragment
MFR1 was amplified by methylation-specific primers (with 3
CpGs in both forward and reverse primers), and these CpGs were
excluded during BISMA analysis. (B) In normal lung, no stretch
of unmethylated CpGs was observed to suggest nucleosome
occupancy. Specific CpG sites were, however, protected which
may indicate possible transcription factor binding (e.g. PPARg,
ER, and ETF). (C–D) Endogenous DNA methylation complicates
interpretation of the patterns found in lung tumor and lung cancer
cell lines. Unmethylated CpGs which fall in a predicted
nucleosome (nuc 3) were, however, observed in the 98 clones
from 7 lung cancer cell lines with little or no Cadm1 gene
expression.
(TIF)
Figure S5 M.SssI maps in normal lung, lung tumor and
lung cancer cell lines in CpGs within the MFRA fragment
(222 bp, 27 CpGs, 2396 to 2180). (A) Annotation of the
MFRA fragment showing the CpGs, predicted nucleosomes with
the Segal, ICM, NuPOP algorithms, and putative binding sites of
lung-specific transcription factors. The maps (B–D) were obtained
with BISMA, where blue boxes representing unmethylated CpGs
(=protected) while red boxes, methylated CpGs. In lung tumors
and lung cancer cell lines, CpG methylation could be endogenous
and/or from the M.SssI treatment. The CpG in the core sequence
of two Sp1 sites are indicated by arrows. (B) In normal lung, DNA
methylation patterns suggest absence of nucleosome occupancy
and possible transcription-factor binding. But clones are also
present with a stretch of unmethylated CpGs that are located in a
predicted nucleosome (nuc 3). (C–D) Endogenous DNA methyl-
ation complicates interpretation of the patterns found in lung
tumor and lung cancer cell lines, but clones are present with a
stretch of unmethylated CpGs that are located in a predicted
nucleosome (nuc 3). In the 86 clones from 7 lung cancer cell lines
with little or no Cadm1 gene expression, the CpGs in the Sp1
binding sites at 2224 and 2211 were mostly unmethylated, which
could be both due to Sp1 binding and nucleosome sliding.
(TIF)
Figure S6 M.SssI maps in first and second trials in
three lung cancer cell lines (B3, A2B1 and BD10). (A)
Location of the five fragments analyzed in the Cadm1 promoter
region that cover 69 CpGs 2944 to +41, relative to the translation
start site, ATG. The maps (B–D) were obtained with BISMA,
where blue boxes representing unmethylated CpGs (=protected)
while red boxes, methylated CpGs. The fragments are presented
with respect to their location i.e. from BFR to TSFR1. In the lung
cancer cell lines, CpG methylation could be endogenous and/or
from the M.SssI treatment. The lung cancer cell lines (B3, A2B1
and BD10) still express Cadm1, with BD10 the lowest. The CpGs
in the core sequence of Sp1 and Zf5 binding sites are indicated by
arrows.
(TIF)
Figure S7 M.SssI maps in six lung cancer cell lines with
little or no Cadm1 gene expression. (A) Location of the five
fragments analyzed in the Cadm1 promoter region that cover 69
CpGs 2944 to +41, relative to the translation start site, ATG.
CpGs are represented by stripes. (B) Methylation maps were
obtained with BISMA, where blue boxes representing unmethy-
lated CpGs (=protected) while red boxes, methylated CpGs. The
fragments are presented with respect to their location i.e. from
BFR to TSFR1. In the lung cancer cell lines, CpG methylation
could be endogenous and/or from the M.SssI treatment. The
CpGs in the core sequence of Sp1 and Zf5 binding sites are
indicated by arrows.
(TIF)
Figure S8 EMSA experiments with PPARg. (A) The
predicted PPARg binding sequence in the Cadm1 promoter was
used as a probe in nuclear extracts from normal lung, a lung
cancer cell line with no Cadm1 gene expression (A2C12), the cell
line A2C12 treated with 5-aza-29-deoxycytidine, and a Caco cell
line used as control. No binding was observed in normal lung and
in the Caco cell line. In A2C12, where binding occurred, no clear
supershift was observed after addition of PPARg antibody, but the
band (arrow) became weak as compared to the sample without the
antibody. (B) Mutated PPARg core sequence led to abolition of
binding. (C) 100x competition with the wild type probe also
abolished binding. Negative controls were A2C12 nuclear extracts
with no added probes. EMSA probes: WT_F 59 tctcgcggtca-
gactctccgacca 39, WT_R 59 tggtcggagagtctgaccgcgaga 39, MUT_F
59tctcgctggctgactctccgacca 39, MUT_R 59 tggtcggagagtcagccagc-
gaga 39. Antibody PPARgamma (H-100) sc-7196X Sta Cruz
Biotechnology.
(TIF)
Figure S9 Chromatin analysis with micrococcal nucle-
ase (MNase) in mouse lung cancer cell lines. (A) DNA
fragments after MNase digestion of chromatin and ‘naked’
genomic DNA in a lung cancer cell line (A2C12). No PCR
product was obtained in the ‘naked’ genomic DNA (right panel).
(B) Normal PCR products with different primers designed on
predicted nucleosomes and 2 mL of MNase-digested chromatin as
template in the lung cancer cell lines. The samples were analyzed
and loaded onto the gel in the same order as given above. Shown
are also two cell lines that were treated with 5-aza-dC, and a ‘blind’
control uncharacterized cell line (AEII) which does not express
Cadm1. On the upper left cornerof eachgel arethe primer pairs and
the size of products. The quantity of PCR products of ‘middle’
primers (middle panel) was higher than those in which one primer is
moved towards the left or right border of a nucleosome (left and
right panels, respectively). Undigested genomic DNA from a lung
cancer cell line (GA3) was used as positive control.
(TIF)
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PLoS ONE | www.plosone.org 18 June 2012 | Volume 7 | Issue 6 | e38531Figure S10 Chromatin analysis with micrococcal nucle-
ase (MNase) in mouse normal lung. (A) Position of five
predicted nucleosomes obtained with the Segal lab algorithm, the
location of PCR primers used in amplifying fragments after
digestion of chromatin with MNase, and MNase-preferred sites
(CATA). (B) DNA fragment after MNase digestion of chromatin
from seven pooled normal lungs. The quality and concentration of
DNA was checked on 1% ethidium bromide gel before performing
PCR in (C). Normal PCR products with different primers
designed on predicted nucleosomes and 2 mL of MNase-digested
chromatin as template. 1: normal lung chromatin, 2: undigested
genomic DNA from a lung cancer cell line (A2C12) as positive
control, 3: PCR negative control. The primer pair nuc5AF/5R
amplified an additional fragment in undigested genomic DNA.
(TIF)
Figure S11 ChIP experiments with H2A using native
and crosslinked chromatin in lung cancer cell lines. (A)
Position of predicted nucleosomes obtained by different algo-
rithms, location of primers and examples of product size of
amplified fragments. (B) Different products from normal PCR
and 2 mL of ChIP DNA as template following N-ChIP in A2C12.
Loaded onto gel from left in each primer pair after the size marker
(Kb ladder), 1–2: ChIP with different chromatin isolation batches,
3: gel-isolated MNase-digested chromatin, 4: undigested genomic
DNA control. 5: PCR negative control. The primer pair nuc5AF/
5AR amplifies an additional bigger fragment in undigested
genomic DNA. (C) An independent N-ChIP experiment with
A2C12. (D) X-ChIP with different cell lines showing amplification
of same fragments in selected primer pairs. Less PCR product was
obtained with A2B1 which still expresses Cadm1, as compared to
those without expression.
(TIF)
Figure S12 N-ChIP experiments with H2A and H2A.Z in
lung cancer cell lines (A2B1 vs. A2C12). (A) Position of
predicted nucleosomes obtained by different algorithms, location
of primers and examples of product size of amplified fragments.
(B) Different products from normal PCR and 2 ml of ChIP DNA
as template following ChIP with A2B1 and A2C12. Samples were
loaded onto gel as shown for the primer pair nuc1F/1R. The
primer pair nuc5AF/5AR amplifies an additional bigger fragment
in undigested genomic DNA. Some products are already absent in
A2B1. (C) Corresponding qPCR with selected primers, using
20 ng of ChIP DNA as template; results are raw measurements.
(TIF)
Figure S13 N-ChIP experiments with H2A and H2A.Z in
mouse lung tumor. (A) Position of predicted nucleosomes
obtained by different algorithms, location of primers and examples
of product size of amplified fragments. (B) Different products from
normal PCR and 2 mL of ChIP DNA as template following ChIP
with lung tumor. Samples were loaded onto gel as shown for the
primer pair nuc1F/1R. The primer pair nuc5AF/5AR amplifies
an additional bigger fragment in undigested genomic DNA. (C)
Corresponding qPCR with selected primers, using 20 ng of ChIP
DNA as template.
(TIF)
Figure S14 N-ChIP experiments with H2A and H2A.Z in
mouse normal lung. (A) Position of predicted nucleosomes
obtained by different algorithms, location of primers and examples
of product size of amplified fragments. (B) Different products from
normal PCR and 2 mL of ChIP DNA as template following ChIP
with chromatin isolated from seven pooled normal lungs. In this
experiment, the parallel MNase-digested chromatin used as
control was not optimal. Nonetheless, the Input DNA is basically
the same as the MNase control. Samples were loaded onto gel as
shown for the primer pair nuc1F/1R. Some primer pairs gave
weak products even in the positive control (undigested genomic
DNA A2C12). The primer pair nuc5AF/5AR amplifies an
additional bigger fragment in undigested genomic DNA. (C)
Quantitative PCR with selected primers, using 20 ng of ChIP
DNA as template. The ChIP DNA as measured by the qPCR was
obtained from an independent experiment.
(TIF)
Figure S15 Comparison of chromatin status between
A2B1 and A2C12 (A) Position of predicted nucleosomes
obtained by different algorithms, location of primers and examples
of product size of amplified fragments. (B) Comparison of ChIP
DNA with a canonical histone (H2A), histone variants (H3.3,
H2A.Z) and histone modifications (H3K4me3, H3K27me3), in
different fragments analyzed by qPCR. ChIP results are expressed
as Percent Input using Ct values. In A2B1, not all fragments in
ChIP with H3K4me3 and H3K27me3 could be amplified.
(TIF)
Figure S16 Comparison of different histones between
A2B1 and A2C12 (A–B). Examples of ChIP experiments carried
out on the same day in A2B1 and A2C12 in different fragments
analyzedbyqPCR.TheresultisbasedonqPCRvaluesobtainedwith
20 ngofChIPDNAastemplateandusingcalibrationstandardsofa
dilution seriesof gel-isolated MNase-digested chromatinof A2C12.
(TIF)
Table S1 Amplified fragments in the Cadm1 promoter
region to analyze CpG methylation in bisulfite-treated
genomic DNA.
(DOC)
Table S2 Primer sequences used during MNase and
ChIP experiments to interrogate nucleosome position-
ing in the promoter region of mouse Cadm1 gene.
(DOC)
Table S3 Primer combinations and products used
during MNase and ChIP experiments to interrogate
nucleosome positioning in the promoter region of mouse
Cadm1 gene.
(DOC)
Methods S1 Chromatin immunoprecipitation (ChIP):
X-ChIP.
(DOC)
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